Ye Weimin, Held Maria, Lagergren Jesper, Engstrand Lars, Blot William J, McLaughlin Joseph K, Nyrén Olof
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
J Natl Cancer Inst. 2004 Mar 3;96(5):388-96. doi: 10.1093/jnci/djh057.
An inverse association between Helicobacter pylori infection and esophageal adenocarcinoma has been reported that may be attributed to reduced acidity from inducing atrophic gastritis and from producing ammonia. We examined associations between H. pylori infection, gastric atrophy, and the risk of esophageal adenocarcinoma, esophageal squamous-cell carcinoma, and gastric cardia adenocarcinoma in a large population-based case-control study in Sweden.
Self-reported data were obtained during interviews, and serum was collected from 97 patients with incident esophageal adenocarcinoma, 85 patients with incident esophageal squamous-cell carcinoma, 133 patients with incident gastric cardia adenocarcinoma, and 499 randomly selected control subjects. Serum antibodies against whole H. pylori cell-surface antigens (HP-CSAs) and cytotoxin-associated gene A (CagA) antigens were assessed by an IgG enzyme-linked immunosorbent assay and immunoblotting, respectively. Gastric atrophy was assessed by serum levels of pepsinogen I. Multivariable logistic regression with adjustment for potential confounding factors was used to evaluate associations.
H. pylori infection, assayed by HP-CSA or CagA antibodies, was statistically significantly associated with a reduced risk for esophageal adenocarcinoma (for HP-CSA antibodies, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2 to 0.6; for CagA antibodies, OR = 0.5, 95% CI = 0.3 to 0.8; for both, OR = 0.2, 95% CI = 0.1 to 0.5). Gastric atrophy was not associated with the risk for esophageal adenocarcinoma (OR = 1.1, 95% CI = 0.5 to 2.5). Serum CagA antibodies and gastric atrophy were associated with an increased risk for esophageal squamous-cell carcinoma (OR = 2.1, 95% CI = 1.1 to 4.0, and OR = 4.3, 95% CI = 1.9 to 9.6, respectively). The risk of gastric cardia adenocarcinoma was not associated with H. pylori infection. However, gastric atrophy was associated with an increased risk for gastric cardia adenocarcinoma (OR = 4.5, 95% CI = 2.5 to 7.8).
Infection with H. pylori may reduce the risk of esophageal adenocarcinoma, but it is unlikely to do so by atrophy-reduced acidity. Gastric atrophy and infection with CagA-positive strains of H. pylori may increase the risk for esophageal squamous-cell carcinoma.
据报道,幽门螺杆菌感染与食管腺癌之间存在负相关,这可能归因于萎缩性胃炎导致的酸度降低以及氨的产生。我们在瑞典一项基于人群的大型病例对照研究中,研究了幽门螺杆菌感染、胃萎缩与食管腺癌、食管鳞状细胞癌和胃贲门腺癌风险之间的关联。
在访谈期间获取自我报告的数据,并从97例新发食管腺癌患者、85例新发食管鳞状细胞癌患者、133例新发胃贲门腺癌患者以及499例随机选择的对照受试者中采集血清。分别通过IgG酶联免疫吸附测定和免疫印迹法评估针对幽门螺杆菌全细胞表面抗原(HP-CSAs)和细胞毒素相关基因A(CagA)抗原的血清抗体。通过胃蛋白酶原I的血清水平评估胃萎缩。使用对潜在混杂因素进行调整的多变量逻辑回归来评估关联。
通过HP-CSA或CagA抗体检测的幽门螺杆菌感染与食管腺癌风险降低在统计学上显著相关(对于HP-CSA抗体,比值比[OR]=0.3,95%置信区间[CI]=0.2至0.6;对于CagA抗体,OR=0.5,95%CI=0.3至0.8;对于两者,OR=0.2,95%CI=0.1至0.5)。胃萎缩与食管腺癌风险无关(OR=1.1,95%CI=0.5至2.5)。血清CagA抗体和胃萎缩与食管鳞状细胞癌风险增加相关(分别为OR=2.1,95%CI=1.1至4.0,以及OR=4.3,95%CI=1.9至9.6)。胃贲门腺癌风险与幽门螺杆菌感染无关。然而,胃萎缩与胃贲门腺癌风险增加相关(OR=4.5,95%CI=2.5至7.8)。
幽门螺杆菌感染可能降低食管腺癌风险,但不太可能通过降低萎缩性酸度来实现。胃萎缩和CagA阳性幽门螺杆菌菌株感染可能增加食管鳞状细胞癌风险。